Search results for: Clinical-trial

A view shows a production line of levilimab drug at the production facility of BIOCAD company in Saint...

A view shows a production line of levilimab drug, which is undergoing clinical trials in the treatment of complications among the coronavirus disease (COVID-19) patients, at the production facility of BIOCAD biotechnology company in Saint Petersburg, Russia May 20, 2020. REUTERS/Anton Vaganov

RTX7JRTJ

May 20, 2020

Employees are seen next to a production line of levilimab drug, which is undergoing clinical trials in...

Employees are seen next to a production line of levilimab drug at the production facility of BIOCAD company...

Employees are seen next to a production line of levilimab drug, which is undergoing clinical trials in the treatment of complications among the coronavirus disease (COVID-19) patients, at the production facility of BIOCAD biotechnology company in Saint Petersburg, Russia May 20, 2020. REUTERS/Anton Vaganov

RTX7JRTG

May 20, 2020

Employees are seen next to a production line of levilimab drug, which is undergoing clinical trials in...

Employees are seen next to a production line of levilimab drug at the production facility of BIOCAD company...

Employees are seen next to a production line of levilimab drug, which is undergoing clinical trials in the treatment of complications among the coronavirus disease (COVID-19) patients, at the production facility of BIOCAD biotechnology company in Saint Petersburg, Russia May 20, 2020. REUTERS/Anton Vaganov

RTX7JRSU

May 20, 2020

An employee works on a production line of levilimab drug, which is undergoing clinical trials in the...

An employee works on a production line of levilimab drug at the production facility of BIOCAD company...

An employee works on a production line of levilimab drug, which is undergoing clinical trials in the treatment of complications among the coronavirus disease (COVID-19) patients, at the production facility of BIOCAD biotechnology company in Saint Petersburg, Russia May 20, 2020. REUTERS/Anton Vaganov

RTX7G58P

April 28, 2020

A pharmacist displays a sticker with the name of tocilizumab molecule, which is used in the treatment...

A pharmacist displays a sticker with the name of tocilizumab molecule at the pharmacy of Cambrai hospital...

A pharmacist displays a sticker with the name of tocilizumab molecule, which is used in the treatment of rheumatoid arthritis, at the pharmacy of Cambrai hospital, France, April 28, 2020. French Health Ministry mentioned in a statement "promising results" in a clinical trial, led by Paris University Hospital AP-HP, involving tocilizumab. REUTERS/Pascal Rossignol

RTX7G56B

April 28, 2020

A pharmacist displays a box of tocilizumab, which is used in the treatment of rheumatoid arthritis, at...

A pharmacist displays a box of tocilizumab at the pharmacy of Cambrai hospital

A pharmacist displays a box of tocilizumab, which is used in the treatment of rheumatoid arthritis, at the pharmacy of Cambrai hospital, France, April 28, 2020. French Health Ministry mentioned in a statement "promising results" in a clinical trial, led by Paris University Hospital AP-HP, involving tocilizumab. REUTERS/Pascal Rossignol

RTX7G562

April 28, 2020

A pharmacist displays a box of tocilizumab, which is used in the treatment of rheumatoid arthritis, at...

A pharmacist displays a box of tocilizumab at the pharmacy of Cambrai hospital

A pharmacist displays a box of tocilizumab, which is used in the treatment of rheumatoid arthritis, at the pharmacy of Cambrai hospital, France, April 28, 2020. French Health Ministry mentioned in a statement "promising results" in a clinical trial, led by Paris University Hospital AP-HP, involving tocilizumab. REUTERS/Pascal Rossignol

RTX7G561

April 28, 2020

A pharmacist displays boxes of tocilizumab, which is used in the treatment of rheumatoid arthritis, at...

A pharmacist displays boxes of tocilizumab at the pharmacy of Cambrai hospital

A pharmacist displays boxes of tocilizumab, which is used in the treatment of rheumatoid arthritis, at the pharmacy of Cambrai hospital, France, April 28, 2020. French Health Ministry mentioned in a statement "promising results" in a clinical trial, led by Paris University Hospital AP-HP, involving tocilizumab. REUTERS/Pascal Rossignol

RTS36ONH

March 19, 2020

Kylene Karnuth, a clinical lab scientist, works with coronavirus samples as researchers begin a trial...

Researchers set up new labs to help fight coronavirus at the University of Minnesota

Kylene Karnuth, a clinical lab scientist, works with coronavirus samples as researchers begin a trial to see whether malaria treatment hydroxychloroquine can prevent or reduce the severity of the coronavirus disease (COVID-19), at the University of Minnesota in Minneapolis, Minnesota, U.S. March 19, 2020. REUTERS/Craig Lassig

Researchers set up new labs to help fight coronavirus at the University of Minnesota

Kylene Karnuth, a clinical lab scientist, and Robyn Kincaid, technical specialist, work with coronavirus samples as researchers begin a trial to see whether malaria treatment hydroxychloroquine can prevent or reduce the severity of coronavirus disease (COVID-19) at the University of Minnesota in Minneapolis, Minnesota, U.S. March 19, 2020. REUTERS/Craig Lassig

RTS36OM8

March 19, 2020

Kylene Karnuth, a clinical lab scientist at the Microbiology Research Facility, talks with colleagues...

Researchers set up new labs to help fight coronavirus at the University of Minnesota

Kylene Karnuth, a clinical lab scientist at the Microbiology Research Facility, talks with colleagues as researchers begin a trial to see whether malaria treatment hydroxychloroquine can prevent or reduce the severity of coronavirus disease (COVID-19) at the University of Minnesota in Minneapolis, Minnesota, U.S. March 19, 2020. REUTERS/Craig Lassig

RTX6Y5Z7

June 06, 2019

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, attends...

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, speaks to...

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, speaks to his lawyer Ulrike Baumann during his trial in Oldenburg, Germany June 6, 2019. REUTERS/Hauke-Christian Dittrich/POOL

RTX6Y5O1

June 06, 2019

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, speaks to...

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, speaks to...

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, speaks to his lawyer Ulrike Baumann during his trial in Oldenburg, Germany June 6, 2019. REUTERS/Hauke-Christian Dittrich/POOL

RTX6Y5MR

June 06, 2019

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, attends...

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, attends...

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, sits next to his lawyer Ulrike Baumann during his trial in Oldenburg, Germany June 5, 2019. REUTERS/Mohssen Assanimoghaddam/POOL

RTX6XZWI

June 05, 2019

Niels Hoegel, accused of murdering 100 patients at the clinics in Delmenhorst and Oldenburg, attends...

Holmes and Tisdale at the NIH Clinical Center after a breakthrough in sickle cell anemia research

Lynndrick Holmes, 29, walks with Dr. John Tisdale through the National Institute of Health's Clinical Center after the agency announced a breakthrough in sickle cell anemia research in Bethesda, U.S. March 11, 2019. Holmes has shown significant recovery from the disease after participating in Tisdale's clinical trial. REUTERS/Erin Scott

RTX6QPMR

March 11, 2019

Lynndrick Holmes, 29, walks with Dr. John Tisdale through the National Institute of Health's Clinical...

Holmes and Tisdale at the NIH Clinical Center after a breakthrough in sickle cell anemia research

Lynndrick Holmes, 29, walks with Dr. John Tisdale through the National Institute of Health's Clinical Center after the agency announced a breakthrough in sickle cell anemia research in Bethesda, U.S. March 11, 2019. Holmes has shown significant recovery from the disease after participating in Tisdale's clinical trial. REUTERS/Erin Scott

Holmes at the NIH Clinical Center after a breakthrough in sickle cell anemia research

Lynndrick Holmes, 29, discusses his recovery from sickle cell anemia after participating in Dr. John Tisdale's clinical trial at the National Institute of Health's Clinical Center in Bethesda, U.S. March 11, 2019. REUTERS/Erin Scott

Holmes at the NIH Clinical Center after a breakthrough in sickle cell anemia research

Lynndrick Holmes, 29, discusses his recovery from sickle cell anemia after participating in Dr. John Tisdale's clinical trial at the National Institute of Health's Clinical Center in Bethesda, U.S. March 11, 2019. REUTERS/Erin Scott

Holmes at the NIH Clinical Center after a breakthrough in sickle cell anemia research

Lynndrick Holmes, 29, discusses his recovery from sickle cell anemia after participating in Dr. John Tisdale's clinical trial at the National Institute of Health's Clinical Center in Bethesda, U.S. March 11, 2019. REUTERS/Erin Scott

Armed police stand guard as Indonesian Siti Aisyah and Vietnamese Doan Thi Huong, who are on trial for the killing of Kim Jong Nam, the estranged half-brother of North Korea's leader, revisit Menara Clinic at Kuala Lumpur International Airport Two in Sepang, Malaysia October 24, 2017. REUTERS/Lai Seng Sin

RTSU490

December 01, 2016

An IV bag of Takeda Pharmaceutical's drug that is part of a clinical trial for a functional HIV cure...

An IV bag of an HIV medication being tested at the National Institutes of Health is pictured in Bethesda...

An IV bag of Takeda Pharmaceutical's drug that is part of a clinical trial for a functional HIV cure at National Institutes of Health is pictured in Bethesda, Maryland, U.S. November 22, 2016 in this still image from video. REUTERS/Gershon Peaks/RVN

RTSU48V

December 01, 2016

Manni Baez, 30, prepares to receive an antibody infusion of a drug that is part of a clinical trial for...

Manni Baez takes some of his daily antiviral medications for HIV at the National Institutes of Health...

Manni Baez, 30, prepares to receive an antibody infusion of a drug that is part of a clinical trial for a functional HIV cure at the National Institutes of Health in Bethesda, Maryland, U.S. November 22, 2016 in this still image from video. REUTERS/Gershon Peaks/RVN

RTSU48U

December 01, 2016

Manni Baez (L), 30, prepares to receive an antibody infusion of a drug that is part of a clinical trial...

Manni Baez, 30, a clinical trial patient, takes some of his daily antiviral medications for HIV at the...

Manni Baez (L), 30, prepares to receive an antibody infusion of a drug that is part of a clinical trial for a functional HIV cure at the National Institutes of Health in Bethesda, Maryland, U.S. November 22, 2016 in this still image from video. REUTERS/Gershon Peaks/RVN

Neurosurgeon Linda Liau, MD, 49, Professor and Director of the UCLA Brain Tumor Program (C) removes a brain tumour from a patient at the Ronald Reagan UCLA Medical Center in Los Angeles, California, United States, May 26, 2016. Liau has been a neurosurgeon for 25 years and has developed a brain cancer vaccine that is in clinical trials. “It’s a very male-dominated profession... When you walk into the room they assume you’re the nurse or the assistant as opposed to the actual surgeon," Liau said. "I think ultimately the goal would be to be gender-blind completely, so the fact that we’re even talking about having a female president as a novelty is in a way sad." Picture taken May 26, 2016. REUTERS/Lucy Nicholson SEARCH "WOMEN WORKERS" FOR THIS STORY. SEARCH "THE WIDER IMAGE" FOR ALL STORIES

Neurosurgeon Linda Liau, MD, 49, Professor and Director of the UCLA Brain Tumor Program walks out of the operating theatre after successfully removing a tumour from a patient at the Ronald Reagan UCLA Medical Center in Los Angeles, California, United States, May 26, 2016. Liau has been a neurosurgeon for 25 years and has developed a brain cancer vaccine that is in clinical trials. ÒItÕs a very male-dominated profession... When you walk into the room they assume youÕre the nurse or the assistant as opposed to the actual surgeon," Liau said. "I think ultimately the goal would be to be gender-blind completely, so the fact that weÕre even talking about having a female president as a novelty is in a way sad." Picture taken May 26, 2016. REUTERS/Lucy Nicholson SEARCH "WOMEN WORKERS" FOR THIS STORY. SEARCH "THE WIDER IMAGE" FOR ALL STORIES

RTX24LVA

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, looks...

Fauci looks at his mobile device as he prepares to answer reporters' questions about the Zika virus after...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, looks at his mobile device as he prepares to answer reporters' questions about the Zika virus after his remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LV8

January 29, 2016

Dr. Anthony Fauci (L), director of the U.S. National Institute of Allergy and Infectious Diseases, participates...

Fauci participates in a talk with Rubenstein at the Economic Club of Washington at their winter luncheon...

Dr. Anthony Fauci (L), director of the U.S. National Institute of Allergy and Infectious Diseases, participates in a talk with Carlyle Group CEO David Rubenstein (R) at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LUS

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, answers...

Fauci answers reporters' questions about the Zika virus after his remarks at the Economic Club of Washington...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, answers reporters' questions about the Zika virus after his remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LUQ

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers...

Fauci discusses the Zika virus during remarks at the Economic Club of Washington at their winter luncheon...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LUP

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers...

Fauci discusses the Zika virus during remarks at the Economic Club of Washington at their winter luncheon...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LTZ

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, answers...

Fauci answers reporters' questions about the Zika virus after his remarks at the Economic Club of Washington...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, answers reporters' questions about the Zika virus after his remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LTY

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, answers...

Fauci answers reporters' questions about the Zika virus after his remarks at the Economic Club of Washington...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, answers reporters' questions about the Zika virus after his remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LKH

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers...

Fauci discusses the Zika virus during remarks at the Economic Club of Washington at their winter luncheon...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst

RTX24LKE

January 29, 2016

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers...

Fauci discusses the Zika virus during remarks at the Economic Club of Washington at their winter luncheon...

Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, delivers remarks at the Economic Club of Washington at their winter luncheon in Washington January 29, 2016. On Thursday Fauci said a potential candidate for a vaccine for the Zika virus, which may begin clinical trials in people by the end of this year, was based on work done on the West Nile virus. REUTERS/Jonathan Ernst TPX IMAGES OF THE DAY

French Health Minister Marisol Touraine (R) and Gilles Hedan (L), professor of clinical neurology, leave after a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe TPX IMAGES OF THE DAY

French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe

French Health Minister Marisol Touraine and Gilles Hedan, professor of clinical neurology, attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe

French Health Minister Marisol Touraine arrives to attend a news conference in Rennes

French Health Minister Marisol Touraine (L) arrives to attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe

French Health Minister Marisol Touraine arrives to attend a news conference in Rennes

French Health Minister Marisol Touraine arrives to attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe

French Health Minister Marisol Touraine arrives to attend a news conference in Rennes

French Health Minister Marisol Touraine arrives to attend a news conference in Rennes, France, January 15, 2016. One person has been left brain dead and five others are in a serious condition after taking part in a clinical trial in France of an experimental medicine from an unnamed drug company, the French Health Ministry said on Friday. REUTERS/Stephane Mahe

Rosalind Picard, MIT professor and chief scientist at Empatica, and Matteo Lai (R), CEO of Empatica, wear the company's Embrace devices while talking at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder

Rosalind Picard, MIT professor and chief scientist at Empatica, and Matteo Lai (R), CEO of Empatica, wear the company's Embrace devices while talking at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder

Rosalind Picard, MIT professor and chief scientist at Empatica, and Matteo Lai (L), CEO of Empatica, wear the company's Embrace devices while talking at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder

Rosalind Picard, MIT professor and chief scientist at Empatica, wears the company's Embrace device while talking to Matteo Lai, CEO of Empatica, at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder

Rosalind Picard, MIT professor and chief scientist at Empatica, and Matteo Lai (L), CEO of Empatica, wear the company's Embrace devices while talking at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder

Rosalind Picard, MIT professor and chief scientist at Empatica, wears the company's Embrace device while posing for a portrait at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder

Rosalind Picard, MIT professor and chief scientist at Empatica, wears the company's Embrace device while talking to Matteo Lai, CEO of Empatica, at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder

Rosalind Picard, MIT professor and chief scientist at Empatica, and Matteo Lai (L), CEO of Empatica, wear the company's Embrace devices while talking at the Massachusetts Institute of Technology in Cambridge, Massachusetts November 25, 2015. A new wave of wearable computing devices that detect and monitor serious diseases is moving from the laboratory to the market, potentially transforming the treatment of conditions ranging from epilepsy to diabetes and creating business opportunities estimated to be worth tens of billions of dollars. Cambridge, Massachusetts-based Empatica, is developing a wristband designed to alert epilepsy patients and their caregivers of seizures in the hope of averting a dangerous post-seizure condition that can cause sudden, unexpected death. Empatica founder Picard, a Massachusetts Institute of Technology professor and inventor, told Reuters the company has just started large clinical trials using its wristband device on individuals with depression. Picture taken November 25, 2015. To match Insight HEALTH-WEARABLES/FDA REUTERS/Brian Snyder